Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2020

Long non-coding RNA RAMS11 promotes metastatic colorectal
cancer progression
Jessica M. Silva-Fisher
Washington University School of Medicine in St. Louis

Ha X. Dang
Washington University School of Medicine in St. Louis

Nicole M. White
Washington University School of Medicine in St. Louis

Matthew S. Strand
Washington University School of Medicine in St. Louis

Bradley A. Krasnick
Washington University School of Medicine in St. Louis

See next page for additional authors
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Silva-Fisher, Jessica M.; Dang, Ha X.; White, Nicole M.; Strand, Matthew S.; Krasnick, Bradley A.; Rozycki,
Emily B.; Jeffers, Gejae G. L.; Grossman, Julie G.; Highkin, Maureen K.; Tang, Cynthia; Cabanski,
Christopher R.; Eteleeb, Abdallah; Mudd, Jacqueline; Goedegebuure, S. Peter; Luo, Jingqin; Mardis, Elaine
R.; Wilson, Richard K.; Ley, Timothy J.; Lockhart, Albert C.; Fields, Ryan C.; and Maher, Christopher A.,
,"Long non-coding RNA RAMS11 promotes metastatic colorectal cancer progression." Nature
Communications. 11,1. . (2020).
https://digitalcommons.wustl.edu/open_access_pubs/9362

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

Authors
Jessica M. Silva-Fisher, Ha X. Dang, Nicole M. White, Matthew S. Strand, Bradley A. Krasnick, Emily B.
Rozycki, Gejae G. L. Jeffers, Julie G. Grossman, Maureen K. Highkin, Cynthia Tang, Christopher R.
Cabanski, Abdallah Eteleeb, Jacqueline Mudd, S. Peter Goedegebuure, Jingqin Luo, Elaine R. Mardis,
Richard K. Wilson, Timothy J. Ley, Albert C. Lockhart, Ryan C. Fields, and Christopher A. Maher

This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/
open_access_pubs/9362

ARTICLE
https://doi.org/10.1038/s41467-020-15547-8

OPEN

1234567890():,;

Long non-coding RNA RAMS11 promotes
metastatic colorectal cancer progression
Jessica M. Silva-Fisher 1,2, Ha X. Dang1,2,3, Nicole M. White1,2, Matthew S. Strand4, Bradley A. Krasnick4,
Emily B. Rozycki1, Gejae G. L. Jeffers1, Julie G. Grossman 4, Maureen K. Highkin1, Cynthia Tang 1,
Christopher R. Cabanski5, Abdallah Eteleeb1, Jacqueline Mudd4, S. Peter Goedegebuure4, Jingqin Luo2,6,
Elaine R. Mardis 7, Richard K. Wilson7, Timothy J. Ley 1,2, Albert C. Lockhart8, Ryan C. Fields2,4,10 &
Christopher A. Maher 1,2,3,9,10 ✉

Colorectal cancer (CRC) is the most common gastrointestinal malignancy in the U.S.A. and
approximately 50% of patients develop metastatic disease (mCRC). Despite our understanding
of long non-coding RNAs (lncRNAs) in primary colon cancer, their role in mCRC and treatment
resistance remains poorly characterized. Therefore, through transcriptome sequencing of
normal, primary, and distant mCRC tissues we ﬁnd 148 differentially expressed RNAs Associated with Metastasis (RAMS). We prioritize RAMS11 due to its association with poor diseasefree survival and promotion of aggressive phenotypes in vitro and in vivo. A FDA-approved
drug high-throughput viability assay shows that elevated RAMS11 expression increases resistance to topoisomerase inhibitors. Subsequent experiments demonstrate RAMS11-dependent
recruitment of Chromobox protein 4 (CBX4) transcriptionally activates Topoisomerase II alpha
(TOP2α). Overall, recent clinical trials using topoisomerase inhibitors coupled with our ﬁndings
of RAMS11-dependent regulation of TOP2α supports the potential use of RAMS11 as a biomarker and therapeutic target for mCRC.
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olorectal cancer (CRC) is the most common gastrointestinal malignancy in the United States. At the time of
initial diagnosis, 20% of patients present with metastasis,
and of those patients with primary disease approximately 50%
will eventually develop metastatic disease1. Furthermore, the
overall 5-year survival rate for patients with metastatic CRC
(mCRC) is only 14%2,3. Currently, there are numerous therapeutic treatments for patients with mCRC including surgery,
cytotoxic chemotherapy, targeted therapy, immunotherapy,
radiation, and combination strategies. However, there is little pretreatment data that can predict response to treatment and
development of resistance4. While there are promising developments in second-line treatment options for mCRC patients using
cytotoxic agents or targeted agents, the mechanisms driving
metastatic progression remain poorly characterized thus prohibiting effective drug development. Furthermore, response to
second-line treatment is even less effective than ﬁrst line5,6. These
statistics and poor treatment options highlight the critical need
for improved biomarker-driven therapies at the time of diagnosis.
To date, CRC research has primarily focused on the deregulation of protein-coding genes to identify oncogenes and tumor
suppressors as potential diagnostic and therapeutic targets7,8.
While more recent studies have explored the role of microRNAs
in CRC9.10, there is still a lack of studies focusing on long noncoding RNAs (lncRNAs) in mCRC. LncRNAs are typically
greater than 200 nucleotides in length, lack coding potential,
are transcribed by RNA polymerase II, spliced, 5′ capped, and
polyadenylated11. LncRNAs are known to have a diverse range of
biological functions, including serving as critical regulators
in tumorigenesis and metastasis12–18. Furthermore, the clinical
signiﬁcance of lncRNAs can be exempliﬁed by their use as
diagnostic, prognostic, predictive biomarkers, and potential
therapeutic targets19–24. Therefore, the characterization of
lncRNAs, elucidating their function, and assessing their clinical
applicability could signiﬁcantly impact mCRC diagnosis and
treatment.
While transcriptome sequencing has provided an unbiased
method for discovering lncRNAs, existing large-scale sequencing
projects such as The Cancer Genome Atlas Network (TCGA)25
are comprised of predominantly primary tumors lacking matched
metastatic samples. This represents a critical barrier to discovering novel lncRNAs throughout the progression of primary
to metastatic disease correlated to treatment response and resistance. To address this, we have conducted a meta-analysis of
normal, primary, and distant metastatic tissues from CRC
patients across two independent patient cohorts to discover differentially expressed (DE) lncRNAs in metastatic tumors compared with primary tumors, termed RNAs Associated with
Metastasis (RAMS). We have prioritized RAMS11 as it was a top
up-regulated lncRNA in metastasis and associated with poor
disease-free survival across multiple cohorts. We then demonstrate that RAMS11 promotes aggressive phenotypes in vitro and
in vivo. While lncRNAs have been shown to promote tumor
progression26–28, the understanding of their role in treatment
resistance is still unknown. Therefore, we have utilized a drug
screen to discover that RAMS11 promotes resistance to topoisomerase inhibitors and provide mechanistic insight into
RAMS11-dependent topoisomerase II alpha (TOP2α) regulation
to promote mCRC.
Results
LncRNA landscape of mCRC. To identify consistently altered
lncRNAs during mCRC, we performed transcriptome sequencing
and analysis of 37 patients from two independent cohorts. The
ﬁrst cohort includes ten normal colon epithelium, two primary
2

CRC, and fourteen distant mCRC patient samples collected from
Washington University, termed WUSTL cohort. The second
cohort is from a previously published transcriptome sequencing
study by Kim et al.29 using matched normal, primary, and
metastatic samples from 18 CRC patients, termed Kim cohort
(Fig. 1a).
To identify lncRNAs altered in the metastatic samples relative to
primary and normal samples, we performed a meta-analysis of the
WUSTL and Kim cohorts. We identiﬁed 148 DE lncRNAs (FDR <
0.05, fold change > 2) in metastasis, termed RAMS (Fig. 1b and
Supplementary Data 1). Several previously well-known and characterized lncRNAs known to promote oncogenic phenotypes
in CRC or other cancer types were also detected. This includes
increased expression of H19, HULC, CCAT4, and TCONS_I2_
00022545 in mCRC and decreased expression of FENDRR in
metastatic samples30–34 (Fig. 1b). Overall, this serves as a key
meta-analysis from aggressive CRC patient tissues to establish the
mCRC lncRNA landscape.
RAMS11 is upregulated in mCRC. We prioritized our functional
studies on lncRNAs that were highly deregulated and potentially
clinically relevant in mCRC. To prioritize all RAMS, we evaluated
whether their expression correlated with patient outcome. First,
we found that six of the 148 RAMS were associated with diseasefree survival using 232 patients from the TCGA CRC cohort
(RNA-Seq). Among the six RAMS associated with survival in the
TCGA cohort, only RAMS11 was associated with poor survival
from a second cohort of 82 patients (Fig. 1a, c) from the Sveen
study (GSE24549, exon array35). These results indicate that high
levels of RAMS11 in primary tumors may serve as an indication
of poor patient outcome. Notably, RAMS11 was also a top
upregulated lncRNA in metastatic tumors (FPKM = 4.81) as
compared with primary tumors (combined p = 2.56 × 10−10
average fold change = 6.1) and normal tissues (combined p =
2.2 × 10−20, average fold change = 12.9) (Fig. 1d and Supplementary Fig. 1a). We further validated the upregulation of
RAMS11 by qPCR when comparing matched metastatic patient
samples with normal (p = 0.007, two-tailed paired t-test) and
primary (p = 0.024, two-tailed paired t-test) patient samples
(Supplementary Fig. 1b).
Our de novo transcript assembly using the WUSTL cohort
identiﬁed RAMS11 as a ﬁve-exon transcript of 959 nucleotides,
which we conﬁrmed by 5′ and 3′ rapid ampliﬁcation of cDNA ends
(RACE) (Fig. 1d, Supplementary Data 2). Previously, three exons of
the RAMS11 transcript were annotated as LINC01564 (NR_125841)
through a microarray probe-based analysis36 (Fig. 1d). We further
characterized RAMS11 expression in a panel of CRC cell lines.
RAMS11 was highly expressed in a panel of six primary (more than
three-fold increase) and two mCRC cell lines (more than 11-fold
increase) compared with CCD18-Co, a normal colon control
cell line (Supplementary Fig. 1c). Since the cellular localization of
lncRNAs can help decipher their functions, we fractionated
LoVo mCRC cells with high endogenous expression of RAMS11.
As shown in Supplementary Fig. 1d, RAMS11 is predominantly
expressed in the nucleus (89.5%), with only a 10.5% expression
in the cytoplasm. Taken together, these results show that RAMS11
is a ﬁve-exon, nuclear localized, lncRNA that is highly expressed
in primary and mCRC cell lines and absent in normal colon
epithelium.
RAMS11 promotes aggressive phenotypes in vitro. To understand RAMS11 functional signiﬁcance, we created a RAMS11
knockout (KO) model by generating two CRISPR/Cas9 luciferasetagged cell lines with a genomic deletion of the last four exons of
RAMS11 in the LoVo metastatic colon cancer cell line
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Fig. 1 RNAs associated with metastasis (RAMS). a Analysis pipeline for discovery of metastatic CRC lncRNAs. Shaded gray color boxes (input), orange
color boxes (analysis), and blue color boxes (output/results). b Heatmap of lncRNAs differentially expressed in metastasis compared with primary. Patient
samples are indicated on top row shown as normal (green), primary (orange), and liver metastasis (pink). Heatmap color is scaled by row expression Zscore. c Kaplan–Meir plots showing RAMS11 association with poor disease-free survival in The Cancer Genome Atlas (TCGA) RNA-Seq and exon array
(GSE24549) datasets. Numbers above x-axis are patients at risk at the intervals. p values are inferred from a two-sided logrank test. d Average normalized
RNA-Seq coverage across WUSTL and Kim cohorts. Normal samples are green boxes, primary samples are orange boxes, and metastatic samples are pink
boxes. 5′3′ RACE validated ﬁve-exon sequence is shown below in blue.

(Supplementary Fig. 2a). We conﬁrmed greater than a 99.9%
reduction in our RAMS11 CRISPR KO models (clones referred to
as CRISPR1 and CRISPR2) relative to wild-type cells (Fig. 2a) and
conﬁrmed that the genomic deletion of RAMS11 did not alter the
expression of adjacent genes GCLC and KLH31 (Supplementary
Fig. 2b, c).

We used these genetically engineered cell lines to determine
changes in the invasiveness of cells using Matrigel-coated transwells
in a modiﬁed Boyden chamber assay. There was more than a
60% decrease in invasion of RAMS11 CRISPR KO cells (CRISPR1
p = 0.004, CRISPR2 p = 0.023, two-tailed paired t-test) compared
with wild-type cells (Fig. 2c, e). We also conducted a transient
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Fig. 2 RAMS11 promotes an invasive phenotype. Expression of RAMS11 in a LoVo CRISPR KO, SW620 silenced cells, and b HT29 overexpressing cells (Clone1
and Clone2) as measured by qPCR. c Images of DAPI-stained LoVo RAMS11 CRISPR KO cells and SW620 siRNA silenced cells show decreased invasion
compared with controls. HT29 cell lines overexpressing RAMS11 show increased invasion. d Images of LoVo RAMS11 CRISPR KO cell lines and SW620 cells
transfected with RAMS11 siRNAs show decreased migration. HT29 cell lines overexpressing RAMS11 show increased migration. e, f Quantiﬁcation of invaded
(n = 4) and migrated cells (n = 3) in LoVo and SW620 cells. g, h Quantiﬁcation of invaded (n = 3) and migrated cells (n = 2) in HT29 cells. i RAMS11 CRISPR
KO cells decreased growth on soft agar (n = 2) and RAMS11 overexpressing cells (n = 6) increased growth on soft agar. j, k Quantiﬁcation of soft agar cells.
All data are presented as mean values ± s.d, analyzed by two-tailed paired t-test, and repeated more than two times. Bar = 25 μM, *p < 0.05, **p < 0.005,
#p < 0.0005. Source data are provided as a Source Data File.

knockdown of RAMS11 in a second colon cancer metastatic
cell line, SW620, and observed at least 80% knockdown in
two independent siRNAs (Fig. 2a). We saw a 50% decrease of
invaded cells relative to control cells that were transfected with
scrambled siRNA (p < 0.00005, two-tailed paired t-test, Fig. 2c,
e). Conversely, stably overexpressing RAMS11 (Clone1 and
Clone2) in HT29 cells, with low endogenous RAMS11 expression (Fig. 2b), resulted in a 53% increase in cellular invasion
(Clone1 p = 0.008, Clone2 p = 0.042, two-tailed paired t-test)
relative to the empty vector control cell line (Fig. 2c, g). Further,
we rescued the number of invaded cells to wild-type levels with
transient overexpression of RAMS11. Our CRISPR KO models
re-expressing RAMS11 (CRISPR RAMS11 OE) revealed more
than a 60% increase of invaded cells relative to the CRISPR KO
cell lines (CRISPR1 RAMS11 OE and CRISPR2 RAMS11 OE p <
0.00005, two-tailed paired t-test) (Supplementary Fig. 2d, e). We
also observed a 73% decrease in cellular migration in the
4

CRISPR KO cells (CRISPR1 and CRISPR2 p < 0.0005, two-tailed
paired t-test) and more than 67% decrease in SW620 RAMS11
silenced cells (p < 0.05, two-tailed paired t-test) (Fig. 2d, f). In
addition, there was increased migration in HT29 RAMS11 overexpressing cells (Fig. 2d, h). Taken together, this demonstrates
that RAMS11 promotes cellular invasion in CRC.
We next investigated the ability of RAMS11 to promote
anchorage-independent growth as another indication of aggressive oncogenic phenotypes. Using a soft agar colony formation
assay, we detected more than a 66% reduction in colony
formation in the RAMS11 CRISPR KO cell lines relative to the
wild-type LoVo cell line (Fig. 2i, j). Conversely, there was a 30%
increase in colony formation in the RAMS11 overexpressing
HT29 cell lines (Clone1 and Clone2 p < 0.05, two-tailed paired
t-test) compared with the empty vector cell line (Fig. 2i, k). These
combined data show that decreased expression of RAMS11 in
genetically modiﬁed and transient knockdown cell lines mitigates
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aggressive phenotypes, while overexpressing RAMS11 promotes
aggressive phenotypes.
As another hallmark of aggressive phenotypes, we next
assessed the effect of RAMS11 expression on cellular proliferation.
We observed a 27% decrease in proliferation in our CRISPR KO
cell lines (p < 0.05, two-tailed paired t-test) (Supplementary
Figs. 2f, g, and 10). Taken together, our in vitro data demonstrate
that RAMS11 can promote multiple oncogenic phenotypes.
Next, we evaluated whether RAMS11 is broadly deregulated
across cancer types, which would suggest a critical conserved
oncogenic role in cancer progression, which we refer to as an oncolncRNA37. We conducted a pan-cancer analysis of 6984 tissues
comprised of matched and unmatched normal and primary
tumors across 22 different cancer types studied within the TCGA.
This analysis revealed that RAMS11 had elevated expression in
primary tumors compared with normal tissue of origin in
colorectal adenocarcinoma (p < 0.00001) and four additional
cancer types including: lung adenocarcinoma (p < 0.00001), lung
squamous cell carcinoma (p < 0.00001), head and neck squamous
cell carcinoma (p < 0.00001), and kidney renal papillary cell
carcinoma (p < 0.00001) (Supplementary Fig. 3a).
Last, since we found that RAMS11 is an onco-lncRNA
upregulated across cancer types, we determined if RAMS11
also promoted oncogenic phenotypes in additional cancer
types. Therefore, we silenced RAMS11 expression and assessed
invasion in two different histologies of non-small cell lung
cancer, lung squamous (HCC95) and lung adenocarcinoma
(A549), cell line models. We found that silencing RAMS11
expression in both cancer cell lines caused a decrease in cellular
invasion (HCC95 p < 0.05; A549 p < 0.005, two-tailed paired
t-test) (Supplementary Fig. 3b–g). These results indicate that
increased RAMS11 expression promotes oncogenic phenotypes
in multiple cancer types.
RAMS11 promotes tumor growth and metastasis in vivo. Since
our RAMS11 CRISPR KO lines had a signiﬁcant decrease in
cellular proliferation in vitro (Supplementary Fig. 2f, g), we
evaluated tumor growth by injecting RAMS11 CRISPR KO cells
into NOD/SCID immunocompromised mice. Twenty-ﬁve days
after subcutaneous injection of LoVo luciferase-tagged wild-type
and our luciferase-tagged RAMS11 CRISPR KO cells we found a
signiﬁcant decrease (p < 0.0005, two-tailed paired t-test) in both
tumor volume and size in mice injected with RAMS11 CRISPR
KO cells compared with wild-type cells (Fig. 3a–d). These results
indicate that RAMS11 may indeed induce tumor formation and
promote oncogenesis in vivo.
Next, to assess the contribution of RAMS11 to cause metastasis
in vivo, we used two mouse models of metastasis: a tail vein
injection model to study the development of lung metastases and
a hemisplenectomy model to study the development of liver
metastases. For the tail vein model, we injected LoVo luciferasetagged wild-type and our luciferase-tagged RAMS11 CRISPR KO
cells into the tail vein of 5-week-old NOD/SCID mice. We
monitored the mice at day 0, within 30 min to 1 h post injection,
and weekly for metastasis formation with bioluminescence
imaging (BLI). All mice were injected successfully showing
similar luminescence levels determined by BLI at baseline day 0
(Fig. 4a). Further, images from day 7 showed no detectable signal
indicating the internalization of circulating cells throughout the
mouse. There was little or no lung metastasis in mice injected
with RAMS11 CRISPR KO cell lines by day 35 (p = 0.02, twotailed paired t-test) as compared with wild-type cells (Fig. 4a, b).
We continued to monitor lung metastasis for 91 days and
saw signiﬁcantly less lung metastasis in RAMS11 CRISPR KO
cell-injected mice compared with wild-type cell-injected mice

ARTICLE

(p < 0.05, two-tailed paired t-test) (Fig. 4b, c). We also detected
less lung metastasis ex vivo in mice injected with RAMS11
CRISPR KO cells compared with mice injected with wild-type
cells (Fig. 4d). In addition, extracted lungs had little to no tumors
detected by hematoxylin and eosin (H&E) stain and lower levels
of Ki67 staining from RAMS11 CRISPR KO cell-injected mice
compared with wild-type cell-injected mice (Fig. 4e).
We assessed if RAMS11 promoted liver metastasis using the
hemisplenectomy model. LoVo luciferase-tagged wild-type and
luciferase-tagged RAMS11 CRISPR KO cells were injected into
8-week-old NGS mouse spleens38. We detected liver metastasis
by day 7 in mice injected with wild-type cells (Fig. 5a) and
detected signiﬁcantly lower levels of bioluminescence in RAMS11
CRISPR KO cell-injected mice compared with wild-type cellinjected mice by Day 21 (CRISPR1 p = 0.016, CRISPR2 p =
0.008, two-tailed paired t-test, Fig. 5a, b). We excised all mouse
livers and validated the decrease of liver metastasis (Fig. 5c),
decreased liver weights (CRISPR1 p = 0.0000026, CRISPR2 p =
0.00069, two-tailed paired t-test, Fig. 5d), and decrease in overall
liver metastasis area (CRISPR1 p = 0.00021, CRISPR2 p =
0.00018, two-tailed paired t-test, Fig. 5e) in RAMS11 CRISPR
KO cell-injected tumors. Decreased tumor burden and proliferation in RAMS11 CRISPR KO cell livers were further determined
by H&E and Ki67 staining (Fig. 5f). Overall, our cell models
manipulating RAMS11 expression demonstrate the ability of
RAMS11 to promote invasive phenotypes both in vitro and
in vivo.
Drug screen reveals RAMS11 resistance to TOP2α inhibitors.
To implicate RAMS11 in speciﬁc biological processes and establish its clinical importance, we conducted a high-throughput
viability assay using 119 FDA-approved anticancer drugs from
the NIH Developmental Therapeutics Program (Approved
Oncology Drugs Set VI). The FDA-approved anticancer panel
included multiple classes of drugs such as kinase inhibitors,
alkylating agents, antineoplastic antibiotics, anthracycline antibiotics, and antineoplastic agents (topoisomerase inhibitors).
The HT29 RAMS11 overexpressing and control cells were treated
for 72 h to assess cellular viability upon drug treatment (Supplementary Fig. 4a and Supplementary Data 3). The RAMS11
overexpressing cells were resistant to nine drugs as demonstrated
by a greater than three-fold increase in cellular viability when
compared with the empty vector control cell line with the greatest
resistance observed with gemcitabine and ﬂoxuridine (FUDR)
(Supplementary Fig. 4b, c). FUDR, a 5-FU derivative, is commonly used to treat mCRC, while gemcitabine is used in refractory mCRC39–42. Due to 5-FU commonly used to treat mCRC, we
further determined if RAMS11 expression altered drug sensitivity
in treated cells. In our RAMS11 CRISPR KO lines we found a
1.7-fold and 5.8-fold increase in drug sensitivity in CRISPR1
and CRISPR2, respectively, compared with wild-type cells (Supplementary Fig. 5a). Similarly in SW620 cells with transient
silencing of RAMS11 there was a greater than 1.5-fold increase
in drug sensitivity in both siRNAs (siRNA1 fold > 1.53, siRNA2
fold > 1.59) relative to scrambled control wild-type treated
cells (Supplementary Fig. 5b). 5-FU, irinotecan (topoisomerase I
inhibitor (TOP1)), and oxaliplatin (new-generation platinum
compound) are currently used as ﬁrst-line active chemotherapy
options individually or in combination for patients with metastatic disease4,43,44. We did not see a signiﬁcant effect of cell
viability for irinotecan or oxaliplatin using our HT29 RAMS11
overexpressing cells or LoVo RAMS11 CRISPR KO cells (Supplementary Data 3, Supplementary Fig 5c–e). SW620 cells with
silenced RAMS11 also did not have a signiﬁcant effect of cellular
viability for oxaliplatin treatment, but we did detect an increase in
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b

a

c

Fig. 3 RAMS11 induces tumor growth in vivo. a Signiﬁcant decrease in tumor growth in RAMS11 CRISPR KO subcutaneous injected mice. Day 14 CRISPR1
p = 0.01 CRISPR2 p = 0.0002, day 21 CRISPR1 p = 0.00002 CRISPR2 p = 0.0006, day 25 CRISPR1 p = 3.32e−05 CRISPR2 p = 3.28e−05. b Quantiﬁcation
at day 25 showing decreased tumor growth in RAMS11 CRISPR KO lines compared with wild type. c Representative mice showing little to no tumor growth
and d representative resected tumors from mice. Data shown as mean ± SEM and analyzed by two-tailed paired t-test, with n = 10 per group repeated two
times. *p < 0.05, **p < 0.005, #p < 0.0005. Source data are provided as a Source Data File.
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Fig. 4 RAMS11 induces lung metastasis via tail vein mouse model. a Representative mice and b quantiﬁcation showing no lung metastasis in RAMS11
CRISPR KO cell-injected mouse by BLI. Day 28 CRISPR2 p = 0.04, day 35 CRISPR1 p = 0.02 CRISPR2 p = 0.013, day 49 CRISPR1 p = 0.02 CRISPR2 p =
0.01 day 84 CRISPR1 p = 0.05 CRISPR2 p = 0.03, day 91 CRISPR1 p = 0.04 CRISPR2 p = 0.01. c, d Day 91 ex vivo mouse lungs show RAMS11 CRISPR KO
cell-injected mice have decreased lung metastasis by BLI. e Hematoxylin and eosin stain showing metastasis (M) and Ki67 stain. Three independent
tissues were stained per group. Blue bar = 1 mM, black bar = 25 µM. Data shown as mean ± SEM and analyzed by two-tailed paired t-test, with n = 12 per
group repeated two times. *p < 0.05. Source data are provided as a Source Data File.

drug sensitivity to irinotecan (siRNA1 fold > 3.17 and siRNA2
fold > 11.8, Supplementary Fig 5f).
Interestingly, half of the topoisomerase inhibitors assessed
caused at least a two-fold increase in drug resistance in the HT29
6

RAMS11 overexpressing cells including the TOP1 topotecan
hydrochloride (HCl) and four TOP2α inhibitors (doxorubicin
HCl, epirubicin HCl, daunorubcin HCl, and idarubicin HCl
(Fig. 6a, b). To further support our observation that RAMS11

NATURE COMMUNICATIONS | (2020)11:2156 | https://doi.org/10.1038/s41467-020-15547-8 | www.nature.com/naturecommunications

ARTICLE

NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-15547-8

a

b

(Days)

7

14

c

21
Mouse 1

p = 0.008

CRISPR1

Photons/s
(Day 21)

2.50E+08
2.00E+08
1.50E+08
1.00E+08
5.00E+07

3.0

2.8

2.6

2.4

2.2

2.0

1.8

1.6

CRISPR2

WT

Mouse 4

Mouse 3

1.4

1.2

1.0

0.8

0.6

0.4

0.2

CRISPR1

0.00E+08
CRISPR2

Mouse 2

CRISPR2 CRISPR1 Wild type

Wild type

p = 0.01
3.00E+08

Radiance × 106

7.0

6.5

6.0

5.5

5.0

4.5

4.0

3.5

3.0

2.5

2.0

1.5

1.0

0.5

Radiance × 106

3
2

CRISPR2

CRISPR1

0

WT

1

CRISPR1

4

80
60
40
20
0

CRISPR2

Metastatis area (%)

Liver weights (g)

5

p = 0.0001

100

CRISPR2

p = 9.04e–05

6

p = 0.0002

CRISPR1

7

f
120

Wild type

e
p = 2.67e–05

WT

d

Fig. 5 RAMS11 induces liver metastasis via hemisplenectomy mouse model. a Representative mice showing no liver metastasis in RAMS11 CRISPR KO
cell-injected mice by BLI. b RAMS11 CRISPR KO cell-injected mice show a signiﬁcant decrease in liver metastasis by day 21. c Day 21 ex vivo mouse livers
show decreased metastasis in RAMS11 CRISPR KO cell-injected mice by BLI. Wild-type cell-injected mice had d increased liver weights and e liver
metastasis compared with CRISPR KO cell-injected mice. f Hematoxylin and eosin stain of livers showing metastasis (M) and levels of Ki67 stain. Three
independent tissues were stained per group. White bar = 10 µM, black bar = 100 µM. Data shown as mean ± SEM and analyzed by two-tailed paired t-test,
with WT n = 18, CRISPR1 n = 11, CRISPR2 n = 11 per group, experiment was repeated three times. *p < 0.05, **p < 0.005, #p < 0.0005. Source data are
provided as a Source Data File.

overexpression promoted resistance to topoisomerase inhibitors,
we narrowed our focus on clinically relevant drugs that
selectively target the DNA topoisomerase TOP2α, doxorubicin
and epirubicin. Measuring cellular viability in LoVo RAMS11
CRISPR KO cells we showed a 1.5-fold increase in drug
sensitivity with 0.5 µM doxorubicin or 0.7 µM epirubicin treatment compared with wild-type treated cells (p < 0.05, two-tailed
paired t-test, Fig. 6c).
To further support our drug panel ﬁndings, we evaluated
whether RAMS11 regulated TOP2α protein expression. We
observed that RAMS11 overexpressing cell lines had elevated
TOP2α protein expression, whereas our CRISPR KO cells
displayed a decrease in TOP2α protein levels (Fig. 6d). The
decrease in TOP2α expression in our CRISPR KO cells was
rescued by re-introducing RAMS11 expression in these cells
(Fig. 6d). Transient silencing of RAMS11 in SW620 cells also
decreased TOP2α protein and mRNA levels relative to our
scrambled control (Supplementary Fig. 6a, b). To demonstrate
the speciﬁcity of RAMS11 regulation of TOP2α, we conﬁrmed
there was only a decrease of TOP2α mRNA expression by
making primers speciﬁcally targeting TOP2α and not TOP2β
in the LoVo CRISPR KO and SW620 silenced cell lines

(Supplementary Fig. 6b, c). Lastly, we assessed downstream
targets of TOP2α in our CRISPR KO cell lines and observed a
decrease in MLH1 and ERCC2 mRNA levels supporting RAMS11
regulation of TOP2α (Supplementary Fig. 6d). Overall, our highthroughput drug panel established that RAMS11 expression
impacted cellular sensitivity to topoisomerase inhibitors, speciﬁcally inhibitors targeting TOP2α, which led to the discovery
that RAMS11 overexpression increased TOP2α protein expression in colon cancer cell lines. These data highlight the potential
for RAMS11 expression to serve as an important biomarker
to select mCRC patients that may potentially beneﬁt from
topoisomerase inhibitor treatment.
RAMS11 binds to chromobox protein 4 (CBX4) to regulate
TOP2α. Due to the nuclear localization of RAMS11 we hypothesized that it may transcriptionally regulate TOP2α expression to
increase protein levels and promote topoisomerase resistance.
Notably, a recent study found that CBX4 bound to the promoter of
Top2α45. Since CBX4 is known to possess both activation and
repressive activities46,47, and has been found to interact with
lncRNAs47,48, we hypothesized that it could interact with RAMS11
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Fig. 6 RAMS11 expression alters sensitivity to topoisomerase inhibitors. a Cell viability assay comparing HT29 empty vector cells with RAMS11
overexpressing cell lines showing signiﬁcant resistance to various drug classes. b RAMS11 overexpressing cells have increased cell viability compared with
empty vector cells in ﬁve of ten topoisomerase (Topo) inhibitors. c IC50 values of RAMS11 CRISPR KO cell lines (n = 3) with decreased viability to doxorubicin
hydrochloride (HCl) and epirubicin HCl drug treatments. d Protein expression of Top2α in (top) RAMS11 overexpressing cell lines and (bottom) CRISPR KO
cell lines, TOP2α siRNA control cells, and CRISPR cell lines overexpressing (OE) RAMS11. Band intensities were quantiﬁed from the digital image in ImageJ and
are shown normalized to the empty vector or wild-type lane for each target. Samples derived from the same experiment and blots were processed in parallel.
All data are presented as mean values ± s.d. Experiments repeated three times. *Fold change > 1.5. Source data are provided as a Source Data File.

and transcriptionally regulate TOP2α expression through interaction with CBX4. We found an 83-fold and 16-fold enrichment of
RAMS11 bound to CBX4 in LoVo and SW620 cells, respectively, as
determined by an RNA immunoprecipitation (RIP) coupled with
qPCR (Fig. 7a, b). To orthogonally validate these ﬁndings, we
conducted a RNA pull-down assay utilizing a 5′ Bromo-UTP fulllength RAMS11 sense labeled probe and a negative control antisense probe to pull-down proteins that may be bound to RAMS11.
We found that the RAMS11 sense probe was bound to CBX4
protein compared with the antisense probe (Fig. 7c) by Western
blot of nuclear lysates. In order to identify the regions of RAMS11
that bind to CBX4, we conducted in vitro RNA pull down in the
LoVo cell line using four truncated RAMS11 fragments (Supplementary Fig. 7a). We re-validated our previous ﬁndings that fulllength RAMS11 binds to CBX4 and revealed that nucleotides
600–959 of RAMS11 interact with CBX4 protein (Supplementary
Fig. 7b). These orthogonal methods support RAMS11 binding to
CBX4 protein.
We next evaluated if CBX4 interacts with the TOP2α promoter
and whether this was dependent on RAMS11 expression. Binding
of CBX4 to the promoter of TOP2α was conﬁrmed by chromatin
immunoprecipitation (ChIP) coupled with qPCR in LoVo colon
cancer cells. Silencing CBX4 led to a 78% decrease in CBX4
occupancy at the TOP2α promoter in LoVo cells (p = 0.021, twotailed paired t-test, Fig. 7d). Further, we demonstrated this
binding is dependent on RAMS11 expression since there was a
greater than 68% decrease in CBX4 occupancy in the TOP2α
promoter in our RAMS11 CRISPR KO models (p < 0.005,
two-tailed paired t-test, Fig. 7d). We also observed a decrease
in tri-methylation of lysine 4 on the Histone H3 protein subunit
(H3K4me3), a modiﬁcation commonly associated with active
transcription, in CBX4 siRNA treated cells and our RAMS11
8

CRISPR KO models (CRISPR1 p = 0.001 and CRISPR2 p =
0.0008, two-tailed paired t-test, Fig. 7e). Decreased CBX4
occupancy and H3K4me3 at the TOP2α promoter was further
conﬁrmed in the SW620 cell line with transiently silenced CBX4
or RAMS11 (CBX4 p = 0.004, RAMS11 siRNA p < 0.05, twotailed paired t-test, Fig. 7f, g). In addition to demonstrating
endogenous binding of RAMS11 to CBX4 in LoVo and SW620
cells, we found more than 15000-fold enrichment of CBX4
binding to RAMS11 in our HT29 RAMS11 overexpressing cells
compared with empty vector (Fig. 7h). In addition, the HT29
RAMS11 overexpressing cells had increased occupancy of CBX4
(p = 0.0005 and p = 0.004, two-tailed paired t-test) and increased
occupancy of H3K4me3 (p = 0.01 and p = 0.001, two-tailed
paired t-test) at the TOP2α promoter (Fig. 7i, j). Further, we
rescued CBX4 (Fig. 7k) and H3K4me3 (p = 0.005, two-tailed
paired t-test, Fig. 7l) occupancy by re-introducing RAMS11
expression into the LoVo CRISPR KO cells. The decrease in
TOP2α protein expression was conﬁrmed by Western blot in
RAMS11 CRISPR KO and CBX4 silenced cells (Fig. 7m). We also
observed a decrease in cellular invasion when CBX4 or TOP2α
were transiently silenced in LoVo cell lines (Supplementary
Fig. 8a, b). Collectively, these data demonstrate RAMS11dependent CBX4 binding to the TOP2α promoter. Taken
together, we provide evidence of RAMS11-dependent CBX4
regulation of TOP2α to induce the metastatic phenotype in CRC
(Fig. 8).
Discussion
In the current study we performed transcriptome sequencing of
matched normal, primary, and distant metastatic patient samples
to identify lncRNAs associated with metastatic progression that
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Fig. 7 RAMS11 binds to chromobox 4 (CBX4) to regulate expression of Top2α mRNA and protein. RNA immunoprecipitation (RIP) shows binding of
RAMS11 to CBX4 and not negative control IgG in a LoVo and b SW620 cells. c RNA pull down of 5-Bromo-UTP full-length RAMS11 probe showing binding of
CBX4 by Western blot in LoVo and SW620 cells. d–g Decreased binding of CBX4 and active histone mark H3K4me3 at TOP2α promoter with silenced
RAMS11 expression in chromatin immunoprecipitation (ChIP) assay. IgG n = 2, CBX4 n > 3, H3K4me3 n > 2. h RIP showing increased binding of RAMS11 to
CBX4 in HT29 RAMS11 overexpressing cells. i, j ChIP of CBX4 and H3K4me3 shows increased binding to TOP2α promoter in HT29 RAMS11 overexpressing
cells. IgG n = 3, CBX4 n = 3, H3K4me3 n = 2. k, l ChIP of CBX4 and H3K4me3 in CRISPR KO cells with RAMS11 overexpression (OE) rescue at TOP2α
promoter. IgG n = 2, CBX4 n = 2, H3K4me3 n = 3. m Protein expression of TOP2α and CBX4 in LoVo (top) and SW620 cell lines (bottom). Band
intensities were quantiﬁed from the digital image in ImageJ and are shown normalized to the wild-type lane for each target. Samples derived from the same
experiment and blots were processed in parallel. Fold change normalized expression to actin is shown below gel. All data are presented as mean values ±
s.d, analyzed by two-tailed paired t-test. Experiments repeated more than two times. *p < 0.05 **p > 0.005, #p < 0.0005. Source data are provided as a
Source Data File.

could serve as a resource for further functional characterization
and biomarker studies. To exemplify this, we prioritized RAMS11
since it was overexpressed in primary and mCRC tumors and its
expression correlated with poor disease-free survival. This
demonstrates the potential utility of RAMS11 expression as a
marker to stratify high-risk patients. Supporting our clinical
ﬁndings, we were able to conﬁrm that RAMS11 promoted
oncogenic phenotypes in vitro and in vivo in several cancer types.
To assess the clinical potential of RAMS11 and elucidate its
regulatory mechanism for promoting aggressive phenotypes we
used a high-throughput drug assay. We found that antimetabolites
gemcitabine and ﬂoxuridine had the most signiﬁcant increase in
cellular viability when RAMS11 was overexpressed. We also found
that RAMS11 promoted resistance to more than half of the topoisomerase inhibitors screened. Currently, the elevated expression of
TOP2α in primary and mCRC patients49–51 has served as the
rationale for using anthracylines to treat select patients with mCRC.
This can be exempliﬁed by an ongoing phase II study to investigate
the efﬁcacy of epirubicin as a second-line treatment for patients
with TOP2α gene ampliﬁcation and oxaliplatin-refractory mCRC52
(EudraCT 2013-001648-79). Our study provides mechanistic
insight into RAMS11-dependent TOP2α regulation in mCRC to
promote resistance to these inhibitors. In addition, despite the
promise of using anthracylines as a mCRC treatment, there are still

many limitations including dose-limiting toxicities, intestinal toxicities, cumulative cardiotoxicity, and off-target effects on TOP2β
leading to TOP2β poisoning53. Fortuitously, RAMS11 speciﬁcally
targets TOP2α, and could be investigated for its therapeutic
potential given the increased use of RNA therapeutics, such as
locked nucleic acids, in clinical trials.
Currently, several topoisomerase inhibitors are currently FDA
approved for treating multiple cancer types and are ﬁrst-line
therapies for breast cancer, bone and soft tissue sarcoma, bladder
cancer, anaplastic thyroid cancer, Hodgkin’s and non-Hodgkin’s
lymphoma, and multiple myeloma53–55. In addition, TOP2α is
used as a proliferation marker in multiple cancer types, including
CRC56,57, and elevated levels of TOP2α expression are associated
with metastasis in prostate cancer, pancreatic cancer, and breast
cancer58–61. Therefore, the clinical impact of our study extends
beyond mCRC and affects a broader patient population given the
widespread use of FDA-approved topoisomerase inhibitors coupled with the altered expression of RAMS11 across multiple solid
tumors.
Overall, our understanding of how lncRNAs promote metastasis in CRC patients may have tremendous biological and clinical
signiﬁcance. To address this, our study used patient samples to
characterize the landscape of lncRNA expression throughout the
progression of primary to mCRC. We also show that lncRNA
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Fig. 8 RAMS11 identiﬁcation and model in metastatic colorectal cancer. Process of identifying RAMS11 and model showing RAMS11 CBX4 complex binding
to Top2α promoter to increase metastatic phenotype.

RAMS11 directly affects mCRC biology, including promoting an
aggressive phenotype and correlating with treatment response
and resistance.

Survival analysis. Survival analysis was performed using the Cox proportional
hazard model with R survival package 2.37-7 2014 (https://CRAN.R-project.org/
package=survival). The median expression of RAMS11 within a cohort was used to
stratifying patients into low and high RAMS11 expression groups. Kaplan–Meier
curves were plotted using the R survplot package 0.0.7 2014 (http://www.cbs.dtu.
dk/~eklund/survplot/).

Methods
Patient samples and RNA sequencing. Patients were enrolled at Washington
University School of Medicine in St. Louis and informed consent was obtained
under an IRB-approved protocol. Adjacent normal, primary, and liver metastasis
tissues were resected from mCRC patients and fresh frozen prior to RNA extraction (Supplementary Data 4). PolyA cDNA libraries were constructed using NuGen
Ovation Kit V2, and paired-end sequencing was performed on Illumina HiSeq
2000. RNA-Seq data from Kim cohort was downloaded from NCBI GEO
(GSE50760). TCGA RNA-Seq pre-aligned bam ﬁles were downloaded from the
Cancer Genomics Hub (http://cghub.ucsc.edu/).

RNA-Seq data analysis. The human reference genome assembly version GRCh38/
hg38 and the corresponding gene annotations were used in RNA-Seq analysis.
Gene annotations were combined from Gencode v2362, RefSeq downloaded from
the UCSC Genome Browser63, and the Broad lncRNA catalog64. Redundant
transcripts were removed and overlapping transcripts were assigned to the same
gene. RNA-Seq reads were aligned to the human genome using Tophat 2.0.865.
Transcript assemblies were generated using Cufﬂinks 2.1.166. FeatureCounts
v1.5.067 was used to generate fragment counts for individual transcripts requiring a
mapping quality score ≥ 1. FPKM was calculated using transcript fragment counts.
For DE analysis, the transcript with highest FPKM among isoforms were selected
to represent a gene locus, similar to our previous approach68. EdgeR 3.8.669 was
used to perform a TMM normalization and DE analysis using the raw fragment
counts. In the meta-analysis, DE p values were combined using the Stouffer
method70 and fold change was averaged between WUSTL and Kim cohorts.
RAMS were deﬁned as lncRNAs that were not tissue speciﬁc and DE between
metastasis versus primary tumor and between metastasis versus normal tissue
(FC ≥ 2, FDR ≤ 0.05).

Exon array data analysis. We repurposed the Affymetrix exon array for lncRNA
analysis by realigning the probe set sequences against the human transcript
sequences using SeqMap 1.0.1271 allowing one mismatch. Only probe sets consisting of probes that were uniquely aligned to transcripts from the same gene were
retained. Exon array expression was processed and normalized using Affymetrix
Power Tool 1.18 (https://www.thermoﬁsher.com).
10

Cell culture. Colon cancer cell lines CCD18-Co and SW480 were a kind gift from
Dr David Shalloway at Cornell University. All other colon cell lines (HT29, HT-15,
DLD1, SW620, Caco-2, HCT-116, and RKO) were a kind gift from Dr A. Craig
Lockhart at Washington University. LoVo cell lines were purchased from ATCC
(ATCC CCL-229). HCC95 and A549 cell lines were a kind gift from Dr Lauren
Michel and Dr Brian Van Tine, respectively, from Washington University. SW620
cells were grown in DMEM (Invitrogen, Carlsbad, CA) with 10% fetal bovine
serum (Sigma, St. Louis, MO), and 1% penicillin/streptomycin (Invitrogen,
Carlsbad, CA) complete media. LoVo cells were grown in DMEM/F12 (Invitrogen)
with 10% fetal bovine serum, and 1% penicillin/streptomycin complete media.
HT29, HT-15, DLD1, and Caco-2 cells were grown in McCoys (Invitrogen) with
10% fetal bovine serum and 1% penicillin/streptomycin, and all other cells were
grown in RPMI (Invitrogen) with 10% fetal bovine serum, and 1% penicillin/
streptomycin complete media.
Rapid ampliﬁcation of cDNA ends (RACE). 5′ and 3′ RACE was done using the
GeneRacer Kit (Invitrogen) according to the manufacturer’s instructions. RACE
PCR products were obtained with Platinum Taq High Fidelity (Invitrogen) using
the GeneRacer primer (supplied) and a gene-speciﬁc primer found in Supplementary Data 5. Products were visualized on a 2% agarose gel and puriﬁed by gel
extraction (Qiagen, Germantown, MD). This product was then cloned into pcr4TOPO vector (Invitrogen) and grown in TOP10 E. coli. Clones were sequenced
with the M13 forward primer at the Protein and Nuclei Acid Chemistry Laboratory
at Washington University.
Generation of RAMS11 silenced and overexpression cells. LoVo RAMS11
CRISPR KO cell lines were generated through the Genome Engineering and iPSC
center at the Washington University. CRISPR/Cas9 was used to create a genomic
deletion of the last four exons of RAMS11 in LoVo metastatic colon cancer cells
(Supplementary Fig. 2a). We used two different cell clones for the described
experiments. In addition, we silenced expression of RAMS11 using custom silencer
select RNAs (siRNAs) targeting RAMS11, CBX4, TOP2α, or a negative scrambled
control (Invitrogen). siRNA sequences are listed in Supplementary Data 5.
Full-length RAMS11 transcript was PCR ampliﬁed from LoVo cells and cloned
into the pCFG5-IEGZ vector (a kind gift from Dr Ron Bose, Washington
University). Full-length RAMS11 inserts were conﬁrmed with Sanger sequencing at
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the Protein and Nuclei Acid Chemistry Laboratory at Washington University.
Retroviral infection of cancer cells was performed according to Kauri et al.72.
Brieﬂy, the amyotrophic phoenix cell line was transfected with 10 µg of pCFG5RAMS11 or empty vector control by calcium phosphate precipitation and
incubated for 24 h. Viral supernatants were harvested after an additional 24-h
incubation. Virus was added to cells seeded in six-well dishes in the presence of 8
µg/mL polybrene (Sigma). Cells were centrifuged at 300 × g for 90 min and fresh
media was added to the plate. After 14 days of Zeocin (Invitrogen) selection cells
were used for assays. HT29 colon cells that had low endogenous expression of
RAMS11 were infected with virus expressing RAMS11 or empty vector for 48 h and
selected with 100 µg/mL Zeocin.
Quantitative real-time PCR. Total RNA was isolated for each CRC cell line using
Takara Bio NucleoSpin RNA (Takara, Mountain View, CA). Total RNA was then
transcribed to cDNA with SuperScript III First strand cDNA system (Invitrogen)
and quantiﬁed using Fast Sybr Green Master Mix (Invitrogen) as per the manufacturer’s protocol. Primer sequences are available in Supplementary Data 5.
Protein detection by Western blot. Western blots were conducted by plating
250,000 representative cancer cells in a six-well dish. For transient knockdown
experiments, the next day cells were transfected at 6.25–25 nM with two independent custom designed siRNAs or a negative scramble control with Lipofectamine RNAiMax (Invitrogen) for 72 h. Cells were then lysed with Tris lysis buffer
(50 mM Tris-HCl, 1% Triton X-100, 131 mM NaCl, 1 mM sodium orthovanadate,
10 mM Na4P207, 10 mM NaF, 1 mM EDTA), run on NuPAGE 4-12% Bis-Tris gel
(Invitrogen) and transferred to nitrocellulose membrane (BioRad, Hercules, CA).
Blots were then probed overnight at 4° with respective antibodies including
TOP2A, CBX4, and ACTIN, then washed with TBST buffer, and then applied with
secondary goat anti-rabbit HRP-linked or goat anti-mouse HRP-linked antibodies
(Thermo Fisher, Waltham, MA). Blots were then washed, visualized with Clarity
Western ECL Substrate (Bio-Rad), and imaged using the ChemiDoc XRS+ System
(Bio-Rad). Band intensities were quantiﬁed from the digital image in ImageJ and
are shown normalized to the control lane for each target. Raw Western blots are
shown in Supplementary Fig. 9. All antibodies and concentrations are listed in
Supplementary Data 6.
RNA immunoprecipitation. RIP coupled to qPCR assays were conducted by isolating nuclear lysates from ten million LoVo or SW620 cells following the NERPER Nuclear and Cytoplasmic Extraction Reagent Kit (Thermo Fisher). Nuclear
lysates were then incubated overnight with 5 µg CBX4 antibody or IgG antibody
isotype control in RIPA wash buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl,
1 mM MgCl2, 1% NP40, 0.5% Na-deoxycholate, 0.05% SDS, 1 mM EDTA) and
SUPERase-in RNAse inhibitor (Invitrogen). The next day 50 µL of Invitrogen
Dynabeads Protein G were added to the antibody lysate/mixture and were rotated
for 1 h at 4°. Next, beads were subsequently washed six times with RIPA wash
buffer using a magnetic bead separator. Protein was then digested with proteinase
K buffer (RIPA buffer, 10% SDS, 10 mg/mL proteinase K), at 55° for 30 min
shaking. RNA was phenol:chloroform:isoamyl alcohol extracted following the
general protocol (Thermo Fisher). Last, gDNA was removed from RNA using
ArcticZymes Heat and Run gDNA removal kit following the manufacturer’s protocol (Tromso, Norway). cDNA was made using SuperScript III First strand cDNA
system as indicated above and qPCR was run with Fast Sybr Green Master Mix and
indicated primers (Supplementary Data 5). Fold enrichment of qPCR results were
calculated following Sigma-Aldrich Data Analysis Calculation Shell by comparing
nonspeciﬁc control IgG antibody raw CTs to CBX4 RNA binding protein CT
normalized against 1% input.
Chromatin immunoprecipitation. ChIP qPCR assays were conducted by ﬁrst
sonicating ﬁve million cells in SDS lysis buffer (1% SDS, 500 mM EDTA, 50 mM
Tris-HCl pH 8). Next, sonicated cells were immunoprecipitated with 5 µg IgG,
CBX4, or H3K4me3 antibodies in ChIP dilution buffer (0.01% SDS, 1.10% Triton
X-100, 1.2 nM EDTA, 16.7 mM Tris-HCl pH 8, 167 mM NaCl), and 1X Halt
Protease and Phosphatase inhibitors overnight with rotation at 4°. The next day
Dynabeads Protein G (Invitrogen) were added to the antibody lysate mixture and
rotated for 1 h. Bead/lysate mixture was then washed once with low salt wash buffer
(0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl pH 8, 150 mM NaCl),
then high salt buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl
pH 8, 500 mM NaCl), lithium chloride wash buffer (0.25 M lithium chloride, 1%
NP40, 1% sodium deoxycholate, 1 mM EDTA, 10 mM Tris-HCl pH 8), and ﬁnally
two washes with Tris-HCl EDTA buffer (10 mM Tris-HCl pH 8, 1 mM EDTA).
DNA was eluted by incubating beads for 30 min at room temperature with SDS
elution buffer (1% SDS, 0.1 M sodium bicarbonate), followed by 1.25 M NaCl and
2.5 mg/mL RNAse A at 95° for 15 min shaking followed by addition of proteinase
K buffer (1 µL 10 mg/mL proteinase K, 5 µL 0.5 µM EDTA, 10 µL 1 M Tris pH 7.5)
shaking at 60° for 15 min. DNA was then isolated using phenol:chloroform:isoamyl
alcohol extraction following the general protocol as mentioned above. DNA was
diluted by ﬁve and used for qPCR. The % input calculations were determined by
comparing CT values from input DNA and ChIP DNA for the TOP2A target
promoter region using the following equation: %Input = % of starting input
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fraction × 2[CT(input)−CT(ChIP)]. Primer sequences are available in Supplementary
Data 5.
BrU-labeled RNA pull down. Full-length RNA probes and fragmented RAMS11
probes were made using the Promega Riboprobe in vitro transcription kit from
2.5 µg of linearized DNA in the pGEM-3Z vector (Madison, WI). Antisense probes
were made by in vitro transcription from the SP6 promoter. RAMS11 RNA pulldown experiments were performed in LoVo and SW620 nuclear lysates following
the RiboTrap Kit manufacturer’s protocol (MBL, Woburn, MA). Truncated
RAMS11 probes consisted of fragments 1–250, 200–450, 400–650, and 600–959
basepairs of RAMS11. RAMS11 probes were synthesized and subcloned at Gene
Universal (Newark, DE).
Nuclear cytoplasmic isolations. Nuclear and cytoplasmic isolations were conducted using the PARIS Kit (Thermo Fisher) following the manufacturer’s protocol. Total RNA was also collected as described above. Nuclear and cytoplasmic
isolations were calculated by normalizing respective gene to total RNA expression.
Transwell assays. Cell lines were seeded at 300,000 cells in a six-well dish. The
next day cells were transfected with siRNAs targeting RAMS11, TOP2α, CBX4, or
overexpression plasmids. Seventy-two hours later cells were harvested and reseeded
at 200,000 cells on a transwell 8.0 µM permeable membrane support (Corning,
Corning, NY) in 24-well plates for a modiﬁed Boyden chamber assay. A serum
gradient was established with cells plated in serum-free media and complete media
(10% FBS) added to the bottom of the well. For invasion assays, transwells were
precoated with 200 µg/mL Matrigel (Corning) before addition of cells. Cells were
allowed to migrate or invade overnight and then ﬁxed with 4% paraformaldehyde
(Electron Microscopy Sciences, Hatﬁeld, PA), and nuclei were stained with DAPI
(Sigma, 1 µg/µL). A cotton swab was used to remove cells from the top of the
membrane. Migrated DAPI-stained cells were imaged with Q-Capture Pro software
on an Olympus IX70 microscope, quantiﬁed using ImageJ software (http://imagej.
nih.gov/ij/), and statistical signiﬁcance was determined by a Student’s two-tailed
t-test. Four to seven images were taken per transwell membrane at ×20 magniﬁcation. Assays were repeated two to three times.
Soft agar assays. HT29 cells overexpressing RAMS11 and LoVo RAMS11 CRISPR
KO cell lines were resuspended at 75,000 cells in 0.4% Difco soft agar (BD
Bioscience, Franklin Lakes, NJ) and seeded onto a 5% Difco base agar. Cells were
given fresh media every 3 days for around 2 weeks, and once colonies were visible
by eye, cells were stained with 0.5% Crystal Violet (Sigma) for 3 h. Plates were then
imaged using the ChemiDoc XRS+ (Bio-Rad) and counted with ImageJ software.
Average cell counts were used for comparison and statistical signiﬁcance was
determined by a Student’s two-tailed t-test. Assays were repeated three times.
Drug treatments. The NIH approved oncology library of 119 drugs (AOD6 plate
4825-1 and AOD6 plate 4826) was received from the NIH National Cancer
Institute DTP Developmental Therapeutics Program. Drugs were diluted in DMSO
to 1 mM and the well assignments were rearranged so drugs were conﬁned to the
inner 60 wells of 96-well plates. HT29 RAMS11 overexpressing Clone1 and Clone2
cell lines were seeded at 5000 cells per well in a 96-well plate. The next day serial
diluted drug was added to pre-seeded plates in media containing 1% DMSO
vehicle, using a Robbins Hydra 96 microdispenser. Two 96-well plates of cells were
used as vehicle controls. The plates were incubated for 3 days. Percent viability was
scored by incubating cells for 3 h with resazurin sodium (0.023 mg/mL, Sigma
R7017). The reaction was stopped by the addition of SDS (1% ﬁnal concentration).
Fluorescence Ex/Em 540/590 was read in a Biotek Synergy H1 plate reader
(Winooski, VT). The ﬂuorescence values for the vehicle plates were averaged and
percent viability was determined by the formula: Percent viability = (average
vehicle − value)/(average vehicle − average resazurin in media blank) × 100. We
removed drugs that were undetectable, or out of range, by resazurin assay, leaving
118 drugs to assess in the study (Supplementary Data 3). Values with more than a
1.5-fold change in both RAMS11 Clone1 and Clone2 overexpressing cell lines were
used to determine signiﬁcance. Individual drug IC50 assays were done in a similar
manner as described above with CRISPR KO cells. Assays were repeated more than
three times.
In vivo models. The animal studies were reviewed and approved by the
Washington University’s Institutional Animal Care and Use Committee protocol.
For subcutaneous injections, 2e6 LoVo wild-type, RAMS11 CRISPR1, or RAMS11
CRISPR2 luciferase-tagged cells were injected subcutaneously in ten NOD/SCID
mice per group. Weekly tumor size was determined by caliper measurements
comparing length × width × height × 0.5. For post analysis lung tissues and subcutaneous tumors tissues were removed and formalin ﬁxed and parafﬁn embedded.
This experiment was repeated two times.
In the lung metastasis mouse model, 2e6 LoVo wild-type and CRISPR
luciferase-tagged cell models were injected into the lateral tail vein of twelve
5-week-old NOD/SCID mice (Jackson Laboratories, Bar Harbor, MA) per group
using 30-gauge needles. In weekly intervals mice were imaged with the Olympus
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OV100 Small Animal Imaging System (IVIS Spectrum, Caliper, Hopkinton, MA)
in conjunction with the Small Animal Imaging Core (SAIC) at Washington
University. Mice were imaged for 1 min with sequential 5-s exposures.
Luminescence was quantiﬁed using the Living Image Software 3.2 (Caliper). All
micrometastasis were imaged at day 0 (30 min to 1 h) post operation and weekly
for 12 weeks. At the conclusion of the study, mice were sacriﬁced and examined
visually and with bioluminescence for lung metastases in vivo and ex vivo. Lungs
were dissected and formalin ﬁxed and parafﬁn embedded for histological analysis
with H&E and Ki67 staining. This experiment was repeated twice.
For the hemisplenectomy mouse model38, 2e6 LoVo wild-type and CRISPR
luciferase-tagged cells in 50 µL of PBS were injected into the spleen of 6–8-weekold NGS mice (Jackson Laboratories) (WT n = 18, CRISPR1 n = 11, CRISPR2 n =
11) using 30-gauge needles during open laparotomy. Cell injections were followed
with a 50 µL PBS ﬂush. Incisions were closed with sutures and surgical clips. In
weekly intervals mice were imaged with the Olympus OV100 Small Animal
Imaging System (IVIS Spectrum) in conjunction with SAIC. Mice were imaged for
10 s to 1 min exposures. Luminescence was quantiﬁed using the Living Image
Software 3.2 (Caliper). All micrometastasis were imaged at day 7, day 14, and day
21 post operation. At the conclusion of the study, mice were sacriﬁced and
examined visually and by bioluminescence for liver metastases in vivo and ex vivo.
Livers were dissected, weighed, and formalin ﬁxed and parafﬁn embedded for
histological analysis with H&E and Ki67 staining. This experiment was repeated
three times.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.

Data availability
The RNA-Seq data generated in this study (WUSTL cohort) have been deposited in the
dbGaP database under the accession code phs001722. The Kim et al.’s data29 referenced
during the study are available in a public repository from the NCBI Gene Expression
Omnibus under the accession code GSE50760. The source data underlying all ﬁgures are
provided as a Source Data File. All the other data supporting the ﬁndings of this study are
available within the article and its Supplementary Information ﬁles and from the
corresponding author upon reasonable request. A reporting summary for this article is
available as a Supplementary Information ﬁle.
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